Hepcidin/Ferritin Quotient Helps to Predict Spontaneous Recovery from Iron Loss following Blood Donation

Transfusion Medicine and Hemotherapy

Volumn 42, Issue 6, 2015, Pages 390-395

  Lotfi, Ramin ^a,b   Kroll, Christine ^b   Plonné, Dietmar ^c   Jahrsdörfer, Bernd ^a,b   Schrezenmeier, Hubert ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^c Humangenetik Ulm MVZ   (Germany)

Author keywords

Donors; Health research methodology; Hematology; Red cells

Indexed keywords

ERYTHROMYCIN ESTOLATE; ERYTHROPOIETIN; FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN; HEPCIDIN; IRON; PROTEIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; TWISTED GASTRULATION PROTEIN HOMOLOG 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD DONOR; ERYTHROBLAST; FERRITIN BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HEPCIDIN FERRITIN QUOTIENT; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEPLETION; IRON KINETICS; MALE; NORMAL HUMAN; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETICULOCYTE; TRANSFERRIN BLOOD LEVEL;

EID: 84951739057     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000440825     Document Type: Article

References (37)

1. Chen PP, Short TG, Leung DH, Oh TE: A clinical evaluation of the Hemocue haemoglobinometer using capillary, venous and arterial samples. Anaesth Intensive Care 1992; 20: 497-500.
2. James V, Jones KF, Turner EM, Sokol RJ: Statistical analysis of inappropriate results from current Hb screening methods for blood donors. Transfusion 2003; 43: 400-404.
3. Lotfi R, Wernet D, Starke U, Northoff H, Cassens U: A noninvasive strategy for screening prospective blood donors for anemia. Transfusion 2005; 45: 1585-1592.
4. Rippmann CE, Nett PC, Popovic D, Seifert B, Pasch T, Spahn DR: Hemocue, an accurate bedside method of hemoglobin measurement? J Clin Monit 1997; 13: 373-377.
5. Simon TL: Iron, iron everywhere but not enough to donate. Transfusion 2002; 42: 664.
6. Baart AM, van Noord PA, Vergouwe Y, Moons KG, Swinkels DW, Wiegerinck ET, de Kort WL, Atsma F: High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin. Transfusion 2013; 53: 1670-1677.
7. Garry PJ, Koehler KM, Simon TL: Iron stores and iron absorption: effects of repeated blood donations. Am J Clin Nutr 1995; 62: 611-620.
8. Jelkmann W: Regulation of erythropoietin production. J Physiol 2011; 589: 1251-1258.
9. Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de SM, Giardina PJ, Grady RW, Rivella S: Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007; 109: 5027-5035.
10. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
11. Talbot NP, Lakhal S, Smith TG, Privat C, Nickol AH, Rivera-Ch M, Leon-Velarde F, Dorrington KL, Mole DR, Robbins PA: Regulation of hepcidin expression at high altitude. Blood 2012; 119: 857-860.
12. Pasricha SR, McQuilten Z, Westerman M, Keller A, Nemeth E, Ganz T, Wood E: Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica 2011; 96: 1099-1105.
13. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463.
14. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106: 1864-1866.
15. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M: Immunoassay for human serum hepcidin. Blood 2008; 112: 4292-4297.
16. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB: Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1051-1056.
17. Ginzburg Y, Rivella S: Beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011; 118: 4321-4330.
18. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman R, Maxwell PH, Choi P: Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010; 95: 505-508.
19. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S: Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108: 3730-3735.
20. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T: Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014; 46: 678-684.
21. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL: High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096-1101.
22. Tanno T, Noel P, Miller JL: Growth differentiation factor in erythroid health and disease. Curr Opin Hematol 2010; 17: 184-190.
23. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, Lee YT, Goodnough JB, Harandi O, Ganz T, Paulson RF, Miller JL: Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114: 181-186.
24. Beguin Y: Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003; 329: 9-22.
25. Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA: Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990; 75: 102-107.
26. Mast AE, Schlumpf KS, Wright DJ, Custer B, Spencer B, Murphy EL, Simon TL: Demographic correlates of low hemoglobin deferral among prospective whole blood donors. Transfusion 2010; 50: 1794-1802.
27. Radtke H, Tegtmeier J, Rocker L, Salama A, Kiesewetter H: Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double-blind, placebo-controlled study. Transfusion 2004; 44: 1427-1432.
28. Mast AE, Foster TM, Pinder HL, Beczkiewicz CA, Bellissimo DB, Murphy AT, Kovacevic S, Wroblewski VJ, Witcher DR: Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008; 48: 2197-2204.
29. Tarkun P, Mehtap O, Atesoglu EB, Geduk A, Musul MM, Hacihanefioglu A: Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. Eur J Haematol 2013; 91: 228-235.
30. Casanovas G, Spasic MV, Casu C, Rivella S, Strelau J, Unsicker K, Muckenthaler MU: The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 2013; 98: 444-447.
31. Tanno T, Rabel A, Lee YT, Yau YY, Leitman SF, Miller JL: Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. Transfusion 2010; 50: 1532-1535.
32. Hoffbrand AV, Ganeshaguru K, Hooton JW, Tattersall MH: Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976; 33: 517-526.
33. Furukawa T, Naitoh Y, Kohno H, Tokunaga R, Taketani S: Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci 1992; 50: 2059-2065.
34. Ward RJ, Crichton RR, Taylor DL, Della CL, Srai SK, Dexter DT: Iron and the immune system. J Neural Transm 2011; 118: 315-328.
35. Finch CA, Miller LR, Inamdar AR, Person R, Seiler K, Mackler B: Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 1976; 58: 447-453.
36. Ackrell BA, Maguire JJ, Dallman PR, Kearney EB: Effect of iron deficiency on succinate-and NADHubiquinone oxidoreductases in skeletal muscle mitochondria. J Biol Chem 1984; 259: 10053-10059.
37. Hillgrove T, Moore V, Doherty K, Ryan P: The impact of temporary deferral due to low hemoglobin: future return, time to return, and frequency of subsequent donation. Transfusion 2011; 51: 539-547.